New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€1.4m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€19.1m market cap, or US$21.7m). Reported Earnings • Jun 10
Full year 2025 earnings released Full year 2025 results: Revenue: €56.3m (down 12% from FY 2024). Net loss: €4.43m (loss widened 49% from FY 2024). Announcement • Jun 09
Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026 Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026, at 08:00 W. Europe Standard Time. New Risk • May 24
New major risk - Revenue and earnings growth Earnings have declined by 64% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€15.4m market cap, or US$17.9m). Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Diego Rossano was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 31
Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million. Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi.
The transaction is subject to approval of offer by target shareholders.
illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being. Announcement • Dec 17
Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million. Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl.
The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority. Announcement • Apr 15
Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025 Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time. New Risk • Oct 01
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €3.9m Forecast net loss in 2 years: €206k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€206k net loss in 2 years). Market cap is less than US$100m (€26.5m market cap, or US$29.4m). New Risk • May 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m). New Risk • Apr 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$38.2m). New Risk • Apr 24
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m). New Risk • Oct 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$31.0m). New Risk • Jul 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.0m market cap, or US$42.1m). Board Change • Feb 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 04
Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi. Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023. Announcement • Jan 10
Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi. Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million. Announcement • Nov 13
Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson. Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Farmacosmo S.p.A. (BIT:COSMO) completed the acquisition of a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Announcement • Aug 10
Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi. Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi on August 9, 2022. Board Change • May 09
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.